1 st Quarter Financial Results For Fiscal Year 09 12 August 2008

1. 1st Quarter Financial Results For Fiscal Year 0912 August 2008 Slide 1

2. Highlights of 1Q FY09 Slide 2

3. (US$ ‘000) 1Q FY09 1Q FY08 Change (+/- %) Critical Care Products $3,004 $2,601 15% Drug-eluting stents 7,233 2,381 204% Other Interventional Products 6,822 4,289 59% Total Product Revenues 17,059 9,271 84% NM Licensing and Royalty Revenues 40,981 5,124 TOTAL REVENUES $58,040 $14,395 303% Highlights of 1Q FY09 • Record Product Revenue in 1Q FY09 of US$17.1 million. • 84% increase in product revenues for the quarter • More drug-eluting stent revenue in Q1 FY 2009 than in all of FY 2008 • Within management’s expectation and earlier guidance of US$65 - US$75 million revenue (without consolidation of JWMS) Slide 3

4. Highlights of 1Q FY09 • Recorded US$7.2 million sales of drug-eluting stents in first full quarter of sales of BioMatrix. • BioMatrix comprises 39% of total product revenue, 93% of drug-eluting stent revenue; • 204% growth in drug-eluting stents compared to same quarter in the last corresponding period • Long-term goal – 10% European market share in three years +204% Slide 4

5. Positive Early Market Acceptance of BioMatrix • BioMatrix commercially launched in April 2008. • Key geographies include: Germany, Latin America, Middle East, other European countries • Early market acceptance of BioMatrix is highly positive • Other key markets awaiting regulatory approval • Future catalysts • Sales momentum • Opportunities to participate in business tenders that occur later in the year • Continued regulatory progress • Clinical data Slide 5

6. LEADERS Trial • One of four corporate objectives is to achieve strong clinical data. • Pending results from LEADERS trial scheduled to be presented at fall industry meetings • LEADERS trial considered landmark: • First to compare biodegradable polymer versus non-biodegradable polymer drug-eluting stent; • First to include “all comers” in trial protocol • Impact of LEADERS trial results – if positive • Enhance our clinical-evidenced marketing • Competitive discussion point – moves Biosensors to a different level • Biosensors visibility enhanced Slide 6

7. Update on China • Our goal has not changed – become the #1 stent company in Asia market • JWMS achieved outstanding results in Q1 FYE 31 March 2009 • Revenues in excess of US$12.0 million – business is highly profitable • Biosensors’ agreement to acquire remaining 50% of JWMS from Weigao continues to be delayed • Chinese government and other approvals required; • New regulations may cause additional delays; • Acquisition agreement expires on 30 September 2008 • Continued delays and changing environment increase concern regarding our ability to complete this transaction • Discussions with Weigao continue • Alternative plans in discussion for Biosensors Slide 7

8. Others • Terumo relationship • License agreement for non-USA market modified • No change with respect to sales in Japan • Restructuring efforts • US downsizing on-going – headcount reduction to be completed by 30 September 2008 • Plans regarding Occam to be finalized by 30 September 2008; closing or sale to be completed thereafter • Organization • New COO – Jack Wang • Other positions continue to be determined • CEO headquartered in Singapore • R&D pipeline • Projects progressing as planned • Focus upon polymer-free and product improvements Slide 8

9. Financial Results Slide 9

10. Questions & AnswersSession #1 Slide 10

11. Financial Results - Revenues Product revenues increased 84% in Q1 FYE 31 March 2009 to US$17.1 million from US$9.3 million in Q1 FYE 31 March 2008: Slide 10

12. Financial Results - Revenues Drug-eluting stents More DES sales in Q1 FYE 31 March 2009 than for all of FYE 31 March 2008 BioMatrix launch this quarter BioMatrix 93% of DES revenues for the quarter Pricing and volume consistent with our plans Majority of product placed with distributors Axxion being phased out Other interventional cardiology products Growth of 59% compared to Q1 FYE 31 March 2008 OEM product sales Japan bare metal stents – strong pricing and margins European bare metal stent growth CCP Sales growth of 15% Increases in USA and Europe Slide 11

13. Financial Results – License Revenues US$40.0 million payment from Terumo recognized in current quarter Modification of revenue sharing arrangement for remaining life of agreement for non-US territories, excluding Japan No substantive obligations for Biosensors are required – therefore revenues were recognized Terumo will continue to share revenues on sales in these territories at a reduced rate Revenue sharing percentage remains substantial Percent of revenue sharing for Japanese territory remains unchanged Other license revenues Terumo revenue sharing for current quarter Payments from other licensees Slide 12

14. Financial Results – Gross Profits and Gross Margins Gross profits and gross margins for the quarter are summarized as follows: Overall margins improved due to high percentage of drug-eluting stent revenues Favorable product mix combined with strong sales in Japan offset by lower margins on OEM sales CCP consistent – Asia restructuring project continues Factors affecting future margins – returns, shelf-life, yields, pricing Slide 13

15. Financial Results – Operating Expenses Sales and Marketing Expenses Increase of US$2.4 million or 69% for the quarter Launch expenses – increased personnel, trade shows and branding Sales registry expenses in Europe and Asia General and Administrative Overall spending increase of US$1.2 million or 25% Headcount increase – worldwide basis Infrastructure and professional expenses R&D Consistent with prior year quarter at US$7.1 million compared to US$7.2 million Major expense components – clinical trials (pre-approval), personnel, supplies and professionals Restructuring activities will increase gross profits and reduce G&A and R&D, but Sales and Marketing will continue to increase to support growth Slide 14

16. Financial Results – Others Other expenses are the results of exchange losses – mainly Japanese based JWMS profits continue to be recognized Net of applicable amortization of acquired intangible assets and the elimination of intercompany profits Exceptional Items Impairment charges – US assets impaired in connection with restructuring – US$1.1 million Restructuring charges for US operations – US$1.2 million Allowances for impairment on investments and warrants of licensees – US $2.5 million Excess of fair value of nets assets acquired over cost – US$254,000 Income taxes relate to Terumo license modification revenues – Japan withholding tax and other provisions Balance sheet remains strong- US$77.0 million in cash and equivalents Inventories and receivables to grow Cash flow positive for the quarter – not anticipated in future near term quarters Slide 15

17. Financial Guidance Revenues Previous guidance (total revenues) With consolidation of JWMS (est. 1 Oct. 2008) – US$100 to US$115 million Without JWMS – US$65 to US$75 million Revised guidance for Terumo license modification (US$40.0 million in revenues in 1Q FYE 31 March 2009) With consolidation of JWMS (est. 1 Oct. 2008) – US$140 to US$155 million Without JWMS – US$105 to US$115 million Slide 16

18. Financial Guidance • Profitability • Previous guidance • With consolidation of JWMS – overall losses for the year, profitability possibly achieved during the last half of year • Without JWMS – continued losses with profitability improving over the course of the year • Revised guidance for Terumo license modification (US$40.0 million in revenues in 1Q FYE 31 March 2009) • With consolidation of JWMS (est. 1 Oct. 2008) – Overall profitability for the year achievable; profitability possibly achieved during the last half of the year • Without JWMS – decreasing losses over next three quarters – improvement due to sales growth and restructuring results Slide 17

19. Conclusion Great Quarter for Biosensors!!!!!!! Successful Launch of BioMatrix Completion of JWMS acquisition appears difficult Alternative plans Terumo license modification had a very positive effect upon our business Progress continues Clinical R&D Restructuring China Risks remain Early in the launch cycle Slide 18

20. Questions and AnswersSession #2 Slide 18